| Patent Number |
Title Of Patent |
Date Issued |
| 7622278 |
Compositions and methods for diagnosing or treating psoriasis |
November 24, 2009 |
| In one aspect, the present invention provides isolated nucleic acid molecules that encode a CAN-1 polypeptide, or an STG polypeptide. In another aspect, the present invention also provides isolated STG polypeptides, isolated CAN-1 polypeptides, and isolated SEEK-1 polypeptides. In an |
| 7592429 |
Sclerostin-binding antibody |
September 22, 2009 |
| Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided. |
| 7585954 |
Antibodies for diagnosing psoriasis |
September 8, 2009 |
| The present invention provides nucleic acid molecules, polypeptides, antibodies and methods for the diagnosis and/or treatment of psoriasis. |
| 7572899 |
Compositions and methods for increasing bone mineralization |
August 11, 2009 |
| Nucleic acids relating to human TGF-.beta. binding proteins are disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules. |
| 7544675 |
Chemical compounds with dual activity, processes for their preparation and pharmaceutical compos |
June 9, 2009 |
| The present invention concerns chemical compounds combining affinity and antagonism against the human m3 muscarinic receptor with activity as selective phosphodiesterase IV (PDE IV) inhibitors, processes for preparing them, pharmaceutical compositions containing them and their use as |
| 7507542 |
Method for regulating immune function using the FOXP3 protein |
March 24, 2009 |
| Isolated nucleic acid molecules are provided which encode Fkh.sup.sf, as well as mutant forms thereof. Also provided are expression vectors suitable for expressing such nucleic acid molecules, and host cells containing such expression vectors. Also provided are pharmaceutical compoun |
| 7473697 |
2-Oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy an |
January 6, 2009 |
| This invention relates to new 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives of formula (1) having anticonvulsant activity which are useful as therapeutic agents for the treatment or prevention of epilepsy and other neurological disorders. The invention also concerns |
| 7465549 |
Methods for identifying agents that bind a levetiracetam binding site (LBS) or compete with LEV |
December 16, 2008 |
| The present invention is drawn to methods of characterization of the properties and functions of SV2 proteins. The invention further includes methods of identifying compounds or agents which modulate the activity of SV2 proteins. Included in these methods is the identification of com |
| 7381821 |
Piperazine derivatives and their use as synthesis intermediates |
June 3, 2008 |
| The present invention relates to new enantiomerically pure piperazine derivatives of formula (I) wherein Y represents hydroxy or a leaving group and n is 1, 2, 3, 4 or 5, and to their use as synthesis intermediates, especially for the preparation of pharmaceutically active compounds |
| 7361668 |
Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic |
April 22, 2008 |
| The invention concerns quinuclidine derivatives of formula I or II wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention show high affinities for m3 and/or m2 muscarinic receptors and are particularly sui |
| 7358276 |
2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
April 15, 2008 |
| The invention concerns 2-oxo-1-pyrrolidine derivatives of formula I, ##STR00001## wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals.The compounds of the invention are particularly suited for treating neurological disorders such as |
| 7244747 |
Imidazole derivatives, processes for preparing them and their uses |
July 17, 2007 |
| The present invention relates to imidazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. |
| 7220579 |
Identification of the gene causing the mouse scurfy phenotype and its human ortholog |
May 22, 2007 |
| Isolated nucleic acid molecules are provided which encode Fkh.sup.sf, as well as mutant forms thereof. Also provided are expression vectors suitable for expressing such nucleic acid molecules, and host cells containing such expression vectors. Utilizing assays based upon the nucleic |
| 7199241 |
Process for preparing (S) and (R)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide |
April 3, 2007 |
| The present invention relates to a process for preparing (S)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide and (R)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide by separation of a racemic mixture using multiple column chromatography. |
| 7176310 |
Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents |
February 13, 2007 |
| This invention is directed to compound of the following formula (I): ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as described herein. These compounds and pharmaceutical compositions containing the compounds are useful in treating inflammatory disorders in mammals. |
| 7151112 |
Pharmaceutical uses and synthesis of nicotinamides |
December 19, 2006 |
| This invention is directed to methods of using a compound of the formula ##STR00001## and pharmaceutically acceptable salts thereof, wherein n, X, R.sup.1 and R.sup.2 are disclosed herein, for treating inflammatory events in an animal subject. |
| 7141590 |
Pharmaceutical uses and synthesis of nicotinanilide-N-oxides |
November 28, 2006 |
| Disclosed are nicotinanilide-N-oxide compounds, methods for their production, pharmaceutical compositions which include these compounds, and methods for their use in various therapies. |
| 7135612 |
Identification of the gene causing the mouse scurfy phenotype and its human ortholog |
November 14, 2006 |
| Isolated nucleic acid molecules are provided which encode Fkh.sup.sf, as well as mutant forms thereof. Also provided are expression vectors suitable for expressing such nucleic acid molecules, and host cells containing such expression vectors. Utilizing assays based upon the nucleic |
| 7122682 |
Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of le |
October 17, 2006 |
| The present invention relates to an improved process for the preparation of (S)-(-)-.alpha.-ethyl-2-oxo-1-pyrrolidine acetamide and analogues thereof. The invention also relates to compounds of the general formula (6) wherein R.sub.1 is methyl or ethyl; and R.sub.2 is C?2#191 C?4#191 |
| 7112612 |
N-alkylated GABA compounds, processes for their preparation and their use as medicaments |
September 26, 2006 |
| The present invention relates to N-alkylated GABA (Gamma-aminobutyric acid) compounds, to processes for their preparation, to their use in therapy and to pharmaceutical compositions containing them. More particularly these compounds are useful for treatment of disorders of the centra |
| 7090985 |
Methods for the identification of agents for the treatment of seizures, neurological diseases, e |
August 15, 2006 |
| The present invention is drawn to methods of characterization of the properties and functions of SV2 proteins. The invention further includes methods of identifying compounds or agents which modulate the activity of SV2 proteins. Included in these methods is the identification of com |
| 7087596 |
2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy an |
August 8, 2006 |
| This invention relates to new 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives of formula (1) having anticonvulsant activity which are useful as therapeutic agents for the treatment or prevention of epilepsy and other neurological disorders. The invention also concerns |
| 7083807 |
Pharmaceutical compositions for the controlled release of active substances |
August 1, 2006 |
| The invention relates to pharmaceutical compositions which can be administrated orally, allowing the controlled release of at least one active substance comprising a) the said at least one active substance, b) between 5 and 60% by weight, relative to the total weight of the compositi |
| 6977301 |
Process for preparing (S) and (R)--2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide |
December 20, 2005 |
| The present invention relates to a process for preparing (S)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide and (R)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide by separation of a racemic mixture using multiple column chromatography. |
| 6969556 |
Films, compositions and processes |
November 29, 2005 |
| There is described a substantially planar, self supporting, sheet or film (optionally oriented) which comprises at least one layer comprising a first material which is very highly crystalline polymer (preferably polypropylene of 99% or greater isotacity) together with at least one se |
| 6936633 |
Pyrrolidinone derivatives |
August 30, 2005 |
| The present invention provides pharmaceutical compositions and novel compounds useful in the treatment of conditions mediated by CCR2, MCP-1 or the interaction thereof. The compounds of the present invention are pyrrolidinones and pyrrolidine-thiones. |
| 6916797 |
.alpha.-arylethylpiperazine derivatives as neurokinin antagonists |
July 12, 2005 |
| The invention relates to new .alpha.-arylethylpiperazine of the formula ##STR1##wherein Z represents 0 or S; n' represents 1 or 2; R.sup.2 represents a hydrogen atom or a methyl group; W, Ar.sup.1 and Ar.sup.2 represent various substituents as defined herein;or non-toxic pharmaceutic |
| 6911461 |
2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
June 28, 2005 |
| The invention concerns 2-oxo-1-pyrrolidine derivatives of formula I, ##STR1##wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals.The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy. |
| 6903130 |
Pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders |
June 7, 2005 |
| A use of (S)-(-)-.alpha.-ethyl-2-oxo-1-pyrrolidineacetamide for the manufacture of a medicament for treatment of particular disease and new pharmaceutical compositions comprising (S)-(-)-.alpha.-ethyl-2-oxo-1-pyrrolidineacetamide. |
| 6894059 |
Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
May 17, 2005 |
| The present invention provides 1,4 substituted piperazines, 1,4 substituted piperidines, and 1-substituted, 4-alkylidenyl piperidines compounds. The compounds of the invention are dual acting molecules having both leukotriene inhibition properties as well as antihistaminergic properties. |
| 6884315 |
Method for bonding DVD layers |
April 26, 2005 |
| A method for bonding DVD layers which comprises EB bonding at least two layers of a DVD with an EB curable adhesive composition which consists essentially of at least one epoxy resin and at least one aryl iodonium salt (cationic) photoinitiator and DVDs produced by this method. |
| 6838536 |
Reactive and gel-free compositions for making hybrid composites |
January 4, 2005 |
| A substantially reactive and gel-free composition which comprises: a. particles capable of reaction with a radiation curable resin; b. a coupling agent for modification of the surface of said particles; c. a radiation curable resin; d. a radiation curable salt capable of inhibiting gel f |
| 6828328 |
Analgesic combination of muscarinic agonists |
December 7, 2004 |
| This invention relates to the combination of muscarinic agonists with narcotic analgesics, non-steroidal anti-inflammatory drugs or other analgesic drugs and to their use as antinociception (pain relief) agents. In particular, the invention relates to a combination of a specific class |
| 6818686 |
Water based polymer composition comprising a biopolymer and a polymer resin |
November 16, 2004 |
| The invention relates to a water based polymer composition comprising a biopolymer and a synthetic polymer resin. The biopolymer results from a mechanical thermoplastic processing of a polysaccharide and/or protein starting material using shear forces in the presence of a crosslinking |
| 6818224 |
Use of gellable pharmaceutical compositions in periodontology |
November 16, 2004 |
| A method is described for preparing a fluid pharmaceutical composition which allows the controlled release of at least one active substance. The method involves mixing a therapeutically effective amount of at least one active substance, from 3 to 55% by weight of phospholipid, from 16 to |
| 6806287 |
2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses |
October 19, 2004 |
| The invention concerns 2-oxo-1-pyrrolidine derivatives of formula I, ##STR1##wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals.The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy. |
| 6797713 |
Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
September 28, 2004 |
| The present invention provides 1,4 substituted piperazines, 1,4 substituted piperidines, and 1-substituted, 4-alkylidenyl piperidines compounds. The compounds of the invention are dual acting molecules having both leukotriene inhibition properties as well as antihistaminergic properties. |
| 6790876 |
Radiation curable powder compositions |
September 14, 2004 |
| Powder compositions hardenable by radiation usable for preparing paints or varnishes, specific amorphous polyesters which are comprised within these powder compositions, the use of the paints or varnishes comprising the powder compositions for coating an article as well as articles coate |
| 6784197 |
2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
August 31, 2004 |
| The invention concerns 2-oxo-1-pyrrolidine derivatives of formula (I) wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy. ## |
| 6720079 |
Polyester containing tertiary carboxyl groups, process for its preparation and thermosetting pow |
April 13, 2004 |
| The invention concerns a polyester bearing tertiary carboxyl groups, characterised in that it consists of: (a) 8.1 to 35 moles of an aliphatic or cycloaliphatic of a polyol; (b) 9.1 to 36 moles of an aliphatic, cycloaliphatic or aromatic polycarboxylic acid; (c) 1.6 to 2.8 moles of an |
| 6699502 |
Pharmaceutical compositions for controlled release of active substances |
March 2, 2004 |
| The present invention is directed a pharmaceutical composition which can be administered orally, allowing for the controlled release of at least one active substance. The composition includes at least one active substance, between 5 and 60% by weight, relative to the total weight of the |
| 6686502 |
Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
February 3, 2004 |
| The present invention provides 1,4 substituted piperazines, 1,4 substituted piperidines, and 1-substituted,4-alkylidenyl piperidines compounds. The compounds of the invention are dual acting molecules having both leukotriene inhibition properties as well as antihistaminergic properties. |
| 6660398 |
Powder thermosetting compositions for preparing coatings with low gloss finish |
December 9, 2003 |
| The invention concerns powder thermosetting coating compositions comprising (a) an amorphous polyester containing carboxyl groups, rich in isophthalic acid and neopentylglycol, optionally branched with a polycarboxylic acid or a polyol containing at least three functional groups; (b) a |
| 6635721 |
Powder coating of semicrystalline and amorphous polyesters with crosslinker |
October 21, 2003 |
| Thermosetting powder compositions comprising as binder a mixture of polyesters containing carboxyl groups and of a crosslinking agent having functional groups capable of reacting with the carboxyl groups.The polyesters comprise: (a) a semicrystalline polyester containing carboxyl groups, |
| 6630565 |
Phosphorus-comprising materials, their preparation and use |
October 7, 2003 |
| Phosphorus-comprising polyol, oligomer derived from this phosphorus-comprising polyol, polymer derived from this oligomer, processes for their preparation and uses of these. The present invention relates to a phosphorus-comprising polyol. The invention also relates to an oligomer der |
| 6624218 |
Plasticized polymer compositions |
September 23, 2003 |
| The invention relates to compositions comprising at least one polymer and at least one plasticizer, in which compositions the polymer is semi-crystalline and exhibits a processing temperature equal to or greater than 220.degree. C., preferably 250.degree. C., and the plasticizer is an |
| 6555550 |
Musarinic agonists and antagonists |
April 29, 2003 |
| The present invention provides novel compounds and pharmaceutical compositions thereof useful in the treatment of pain. The compounds of the present invention are azaadamantanes, azanoradamantanes and azahomoadamantanes. |
| 6524804 |
Process for determining antibiotics containing a .beta.-lactam ring in a biological fluid |
February 25, 2003 |
| Disclosed is a process for determining the presence and/or amount of antibiotics containing .beta.-lactam ring present in a biological fluid. The process complexes the antibiotic in the biological fluid with a known amount of recognition agent, and then places the mixture of the biologic |
| 6489329 |
Pharmaceutical compositions for the treatment of rhinitis |
December 3, 2002 |
| A pharmaceutical composition comprising a therapeutically effective amount of a mixture consisting essentially of (i) pseudoephedrine, an individual optical isomer or a pharmaceutically acceptable salt thereof, and (ii) at least one compound selected from 2-[4-(diphenylmethyl)-1-pi |
| 6471970 |
Use of pharmaceutical compositions capable of being gelled in periodontology |
October 29, 2002 |
| A method is described for preparing a fluid pharmaceutical composition which allows the controlled release of at least one active substance. The method involves mixing a therapeutically effective amount of at least one active substance, from 3 to 55% by weight of phospholipid, from 16 to |
